Clinical Trials Logo
  1. Home
  2. Lassa Fever
  3. NCT03889106

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Lassa Fever Clinical Trial

Official title:
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Clinical Trial Summary

Lassa fever carries a treated mortality in hospitalized patients of up to 50%. Lassa fever is often described as being characterized by vascular leak and shock in the terminal phase, but, whilst animal data supports this, there are limited data in humans. Therefore, an aim of this study therefore is to characterize cardiovascular function in patients with Lassa fever, with the ultimate goal of informing future trials of supportive or therapeutic strategies. Ribavirin is the current standard of care. However, the efficacy of ribavirin has not been established in a randomised controlled trial (RCT). There is very limited pharmacokinetic (PK) data on ribavirin in patients with Lassa fever and the optimal dose of ribavirin for an RCT is unknown. Furthermore, there are various hypothesized mechanisms of action of ribavirin, none of which have been investigated in humans with Lassa fever. Further aims of this study therefore are to characterize the PK of ribavirin in Lassa fever, and identify any associations between ribavirin PK parameters, viral load and markers of immune/inflammatory status.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03889106
Study type Observational
Source University of Oxford
Contact
Status Terminated
Phase
Start date March 1, 2019
Completion date October 1, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT00992693 - Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities Phase 2
Completed NCT04285034 - Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Completed NCT03805984 - Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers Phase 1
Recruiting NCT05868733 - A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa Phase 2
Active, not recruiting NCT04794218 - A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath Phase 1
Completed NCT04907682 - Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever Phase 2
Not yet recruiting NCT06212336 - ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Phase 2/Phase 3
Completed NCT04093076 - Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana Phase 1
Not yet recruiting NCT06222723 - LAssa Fever Adjunct Treatment With DEXamethasone Phase 2
Recruiting NCT03655561 - Lassa Fever Clinical Course and Prognostic Factors in Nigeria